Trial · NCT06873945
Registered outcomes38
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 38
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Percentage of participants with absolute Severity of Alopecia Tool (SALT) score less than or equal to 20 | Week 24 | Difference in the percentage of participants with SALT score less than or equal to 20 between ritlecitinib 100 mg once-daily (QD) versus placebo |
| Primary | Part 2: Percentage of participants with TEAEs, SAEs, and AEs leading to discontinuation | Baseline to Follow-up visit (Week 52) | Percentage of participants with events, based on those reported in the study including the safety follow-up period for ritlecitinib 100 mg QD |
| Primary | Part 2: Percentage of participants with clinically significant laboratory abnormalities | Baseline to Follow-up visit (Week 52) | Percentage of participants with clinically significant laboratory abnormalities, based on those reported in the study including the safety follow-up period for ritlecitinib 100 mg QD |
| Secondary | Part 1: Percentage of participants with absolute SALT score less than or equal to 20 | Week 24 | Difference in the percentage of participants with SALT score less than or equal to 20 between ritlecitinib 50 mg QD versus placebo |
| Secondary | Part 1: EU Only: Percentage of participants with Patient Global Impression of Change (PGI-C) response, defined as a score of "moderately improved" or "greatly improved" | Week 24 | Difference in percentage of participants with PGI-C response between ritlecitinib 100 mg QD versus placebo and ritlecitinib 50 mg QD versus placebo |
| Secondary | Part 1: US Only: Percentage of participants with absolute SALT score less than or equal to 20 | Week 36 | Difference in the percentage of participants with SALT score less than or equal to 20 between ritlecitinib 100 mg QD versus placebo |
| Secondary | Part 1: Change from baseline in SALT score | Week 24 | Difference in the mean absolute change from baseline in SALT score between ritlecitinib 100 mg QD versus ritlecitinib 50 mg QD |
| Secondary | Part 1: Percentage of participants with absolute SALT score equal to 0 | Week 24 | Difference in the percentage of participants with SALT score equal to 0 between ritlecitinib 100 mg QD versus placebo and ritlecitinib 50 mg QD versus placebo |
| Secondary | Part 1: Percentage of participants with absolute SALT score less than or equal to 10 | Baseline through Week 24 | Difference in the percentage of participants with SALT score less than or equal to 10 between ritlecitinib 100 mg QD versus ritlecitinib 50 mg QD |
| Secondary | Part 1: Percentage of participants with absolute SALT score less than or equal to 20 | Baseline through Week 24 | Difference in the percentage of participants with SALT score less than or equal to 20 between ritlecitinib 100 mg QD versus ritlecitinib 50 mg QD |
| Secondary | Part 1: Percentage of participants with absolute SALT score equal to 0 | Baseline through Week 24 | Difference in the percentage of participants with SALT score equal to 0 between ritlecitinib 100 mg QD versus ritlecitinib 50 mg QD |
| Secondary | Part 1: Change from baseline in SALT score | Baseline through Week 24 | Difference in the mean absolute change from baseline in SALT score between ritlecitinib 100 mg QD versus ritlecitinib 50 mg QD |
| Secondary | Part 1: Percentage of participants with EBA (Eyebrow Assessment) response, defined as at least a 2-grade improvement from baseline or a score of 3 (among participants without a normal EBA score at baseline) | Baseline through Week 24 | Difference in the percentage of participants with EBA response (among participants without a normal EBA score at baseline) between ritlecitinib 100 mg QD versus ritlecitinib 50 mg QD |
| Secondary | Part 1: Percentage of participants with ELA (Eyelash Assessment) response, defined as at least a 2-grade improvement from baseline or a score of 3 (among participants without a normal ELA score at baseline) | Baseline through Week 24 | Difference in the percentage of participants with ELA response (among participants without a normal ELA score at baseline) between ritlecitinib 100 mg QD versus ritlecitinib 50 mg QD |
| Secondary | Part 1: Percentage of participants with PGI-C response, defined as a score of "moderately improved" or "greatly improved" | Baseline through Week 24 | Difference in the percentage of participants with PGI-C response between ritlecitinib 100 mg QD versus ritlecitinib 50 mg QD |
| Secondary | Part 1: Percentage of participants with absolute SALT score less than or equal to 10 | Week 24 | Difference in the percentage of participants with SALT score less than or equal to 10 between ritlecitinib 100 mg QD versus placebo and ritlecitinib 50 mg QD versus placebo |
| Secondary | Part 1: Percentage of participants with EBA response, defined as at least a 2-grade improvement from baseline or a score of 3 (among participants without a normal EBA score at baseline) | Week 24 | Difference in the percentage of participants with EBA response (among participants without a normal EBA score at baseline) between ritlecitinib 100 mg QD versus placebo and ritlecitinib 50 mg QD versus placebo |
| Secondary | Part 1: Percentage of participants with ELA response, defined as at least a 2-grade improvement from baseline or a score of 3 (among participants without a normal ELA score at baseline) | Week 24 | Difference in the percentage of participants with ELA response (among participants without a normal ELA score at baseline) between ritlecitinib 100 mg QD versus placebo and ritlecitinib 50 mg QD versus placebo |
| Secondary | Part 1: Percentage of participants with absolute SALT score less than or equal to 20 | Week 48 | Difference in the percentage of participants with SALT score less than or equal to 20 between ritlecitinib 50 mg non-responder (NR)--\>ritlecitinib 100 mg QD versus ritlecitinib 50 mg NR--\>ritlecitinib 50 mg QD |
| Secondary | Part 1: Percentage of participants with absolute SALT score less than or equal to 10 | Week 48 | Difference in the percentage of participants with SALT score less than or equal to 10 between ritlecitinib 50 mg NR--\>ritlecitinib 100 mg QD versus ritlecitinib 50 mg NR--\>ritlecitinib 50 mg QD |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06873945/registered